ASR Vermogensbeheer N.V. Makes New $6.04 Million Investment in Edwards Lifesciences Corporation (NYSE:EW)

Key Points

• ASR Vermogensbeheer N.V. acquired a new stake of 83,390 shares in Edwards Lifesciences Corporation valued at approximately $6,044,000 during the first quarter of the year.
• Other large investors, including Citizens Financial Group Inc. and Primecap Management Co., have also adjusted their holdings in Edwards Lifesciences, underscoring significant interest from institutional investors.
• Edwards Lifesciences reported a quarterly EPS of $0.67, beating analyst expectations and showing an 11.9% year-over-year revenue increase, currently having a market cap of $46.08 billion.

ASR Vermogensbeheer N.V. acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 83,390 shares of the medical research company's stock, valued at approximately $6,044,000.

Several other large investors also recently bought and sold shares of EW. Jennison Associates LLC raised its holdings in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Edwards Lifesciences by 55.7% in the fourth quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock valued at $430,367,000 after buying an additional 2,079,642 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $92,631,000. Northern Trust Corp raised its holdings in shares of Edwards Lifesciences by 21.8% in the fourth quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after buying an additional 1,165,845 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $84,787,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the sale, the vice president owned 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president owned 33,496 shares in the company, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,134 shares of company stock valued at $1,311,745 over the last three months. Company insiders own 1.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on EW shares. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Mizuho upped their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Price Performance

Shares of EW stock traded up $0.44 during trading hours on Friday, hitting $78.37. The company's stock had a trading volume of 2,877,353 shares, compared to its average volume of 5,184,443. The business has a fifty day moving average of $77.12 and a 200-day moving average of $74.11. The stock has a market cap of $46.01 billion, a price-to-earnings ratio of 11.28, a P/E/G ratio of 3.77 and a beta of 1.08. Edwards Lifesciences Corporation has a twelve month low of $62.88 and a twelve month high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.70 earnings per share. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.